Sinopep-Allsino ranks in the top 5 of 57 Chinese pharma and biotech firms in a new data-driven ESG evaluation.
A 2026 open-access study in Big Data and Cognitive Computing (Wang et al.) applied a fully machine-learning pipeline to 2024 ESG data from 57 listed Chinese pharmaceutical and biotechnology companies. Existing commercial ESG ratings frequently diverge because of subjective weighting and incomplete data treatment. Wang and colleagues set out to reduce that subjectivity with an end-to-end, data-driven approach that does not rely on expert-assigned weights at any stage.
Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd. placed in the top five under the primary ranking and remained in the top five under three of the four weighting schemes tested.

Figure 1. Top-ranked Chinese pharmaceutical and biotechnology firms in the primary hybrid PCA-CRITIC + TOPSIS ESG ranking of Wang et al. Jiangsu Sinopep-Allsino is highlighted. Normalized scores are relative to the top firm (BeOne Medicines = 100). Exact scores for all 57 companies appear in the Supplementary Materials.
How the ranking was built
The framework has three modules. First, missing values were imputed with MissForest, a random-forest-based method that iteratively predicts missing entries from the observed data. Second, a three-plane feature-selection process—combining unsupervised clustering, feature-importance ranking, and supervised validation with SHAP (SHapley Additive exPlanations)—reduced 70 available indicators to a balanced set of 15 (five environmental, five social, five governance). SHAP values quantify how much each indicator contributes to distinguishing one firm from another. Third, those 15 indicators were weighted using a hybrid PCA-CRITIC method. PCA (principal component analysis) measures how much of the total variance each indicator explains; CRITIC (Criteria Importance Through Intercriteria Correlation) measures how much distinct information an indicator carries relative to the others. The hybrid weight for each indicator is proportional to the product of its PCA and CRITIC scores. Companies were then ranked with TOPSIS (Technique for Order of Preference by Similarity to Ideal Solution), which scores each firm by its distance from a best-case and worst-case profile. No expert-assigned weights enter the process.Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd. placed in the top five under the primary ranking and remained in the top five under three of the four weighting schemes tested.
What set Sinopep apart from most CDMO peers
Most manufacturing-focused companies in the sample showed moderate or low R&D intensity and more typical environmental metrics. Sinopep-Allsino’s 2024 profile combined high R&D investment with relatively low environmental intensity. On the social side, R&D expense growth of 82.12% was among the highest recorded in the 57-company set, and R&D spending equal to 14% of revenue was high for a CDMO. On governance, four board members held PhDs, placing the company in the upper tier on that indicator. On the environmental side, electricity consumption per unit of revenue (28.42), Scope 3 GHG intensity (38.51), and environmental protection tax (0.91) were all low relative to peers, indicating more efficient resource use than most manufacturing-focused firms. These strengths were sufficient to keep Sinopep in the top tier even though female board representation was 0% (the highest-weighted single indicator in the hybrid scheme).
| Indicator | Sinopep value | Relative standing |
|---|---|---|
| R&D expense growth % | 82.12% | Among the highest |
| R&D expense % of revenue | 14.00% | High |
| Board members with PhDs | 4 | High |
| Electricity per revenue | 28.42 | Low (favorable) |
| Scope 3 GHG intensity | 38.51 | Low (favorable) |
| Environmental tax | 0.91 | Very low (favorable) |
| Female board % | 0% | Lowest possible |
Table 1. Selected 2024 ESG indicator values for Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd. from Table S1 of the Supplementary Materials of Wang et al. Relative standing is assessed against the 57-company Chinese pharmaceutical and biotechnology sample under the framework’s direction (higher or lower treated as more favorable).
These strengths were sufficient to keep Sinopep in the top tier even though female board representation was 0% (the highest-weighted single indicator in the hybrid scheme).
What the ranking does and does not claim
The result is specific to the 15 indicators selected by the authors’ pipeline and to the 57-company Chinese pharmaceutical and biotechnology sample. It is not a commercial ESG rating from MSCI, LSEG, or Sustainalytics, and it does not measure product quality, regulatory inspection history, or other dimensions outside the selected metrics.
Full indicator definitions, company-level data from the Supplementary Materials, and the complete ranking are available in the knowledge-center white paper.
| Rank | Company | Score | Rank | Company | Score | Rank | Company | Score | ||
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | BeOne Medicines | 100.0 | 20 | Pharmablock | 74.0 | 39 | Assure Tech | 64.5 | ||
| 2 | WuXi AppTec | 93.5 | 21 | Zhejiang Gongdong | 73.5 | 40 | Asymchem | 64.0 | ||
| 3 | Sichuan Biokin | 91.0 | 22 | Andon | 73.0 | 41 | Hybio | 63.5 | ||
| 4 | Inner Mongolia Furui | 88.5 | 23 | PharmaResources | 72.5 | 42 | HitGen | 63.0 | ||
| 5 | Jiangsu Sinopep-Allsino | 86.5 | 24 | BMC | 72.0 | 43 | Chison | 62.5 | ||
| 6 | Acrobiosystems | 83.5 | 25 | Porton | 71.5 | 44 | Chempartner | 62.0 | ||
| 7 | Intco | 82.5 | 26 | Hangzhou AGS | 71.0 | 45 | Shenzhen Glory | 61.5 | ||
| 8 | Aurisco | 81.5 | 27 | Aidite | 70.5 | 46 | Guangdong Transtek | 61.0 | ||
| 9 | Zhonghong Pulin | 80.5 | 28 | Shenzhen Hepalink | 70.0 | 47 | Mehow Innovative | 60.5 | ||
| 10 | Zhejiang Haisen | 79.5 | 29 | Sino Biological | 69.5 | 48 | Nanjing King-Friend | 60.0 | ||
| 11 | Jenkem | 79.0 | 30 | Zhejiang Jiuzhou | 69.0 | 49 | Qianjiang Yongan | 59.5 | ||
| 12 | Zhejiang Ausun | 78.5 | 31 | Shantou Ultrasonic | 68.5 | 50 | Hangzhou Biotest | 59.0 | ||
| 13 | Pharmaron | 78.0 | 32 | Caina | 68.0 | 51 | Honsun | 58.5 | ||
| 14 | Allmed | 77.5 | 33 | Zhejiang Hisoar | 67.5 | 52 | Edan | 58.0 | ||
| 15 | Ningbo Menovo | 76.5 | 34 | Contec | 67.0 | 53 | Huizhou Jinghao | 57.5 | ||
| 16 | Kingchem | 76.0 | 35 | Guangzhou Jet Bio-Filtration | 66.5 | 54 | Jiangxi Synergy | 57.0 | ||
| 17 | Zhejiang Orient Gene | 75.5 | 36 | Bide | 66.0 | 55 | Anhui Hongyu Wuzhou | 56.5 | ||
| 18 | Zhende | 75.0 | 37 | Jianerkang | 65.5 | 56 | Hangzhou AllTest | 56.0 | ||
| 19 | Zhejiang Tianyu | 74.5 | 38 | Well Lead | 65.0 | 57 | Blue Sail | 55.5 |
Table 2. ESG ranking of 57 Chinese pharmaceutical and biotechnology companies (2024). Scores are based on a composite assessment across environmental, social, and governance indicators. Jiangsu Sinopep-Allsino ranks 5th with a score of 86.5.
| Rank | Company | Score |
|---|---|---|
| 1 | BeOne Medicines | 100.0 |
| 2 | WuXi AppTec | 93.5 |
| 3 | Sichuan Biokin | 91.0 |
| 4 | Inner Mongolia Furui | 88.5 |
| 5 | Jiangsu Sinopep-Allsino | 86.5 |
| 6 | Acrobiosystems | 83.5 |
| 7 | Intco | 82.5 |
| 8 | Aurisco | 81.5 |
| 9 | Zhonghong Pulin | 80.5 |
| 10 | Zhejiang Haisen | 79.5 |
| 11 | Jenkem | 79.0 |
| 12 | Zhejiang Ausun | 78.5 |
| 13 | Pharmaron | 78.0 |
| 14 | Allmed | 77.5 |
| 15 | Ningbo Menovo | 76.5 |
| 16 | Kingchem | 76.0 |
| 17 | Zhejiang Orient Gene | 75.5 |
| 18 | Zhende | 75.0 |
| 19 | Zhejiang Tianyu | 74.5 |
| 20 | Pharmablock | 74.0 |
| 21 | Zhejiang Gongdong | 73.5 |
| 22 | Andon | 73.0 |
| 23 | PharmaResources | 72.5 |
| 24 | BMC | 72.0 |
| 25 | Porton | 71.5 |
| 26 | Hangzhou AGS | 71.0 |
| 27 | Aidite | 70.5 |
| 28 | Shenzhen Hepalink | 70.0 |
| 29 | Sino Biological | 69.5 |
| 30 | Zhejiang Jiuzhou | 69.0 |
| 31 | Shantou Ultrasonic | 68.5 |
| 32 | Caina | 68.0 |
| 33 | Zhejiang Hisoar | 67.5 |
| 34 | Contec | 67.0 |
| 35 | Guangzhou Jet Bio-Filtration | 66.5 |
| 36 | Bide | 66.0 |
| 37 | Jianerkang | 65.5 |
| 38 | Well Lead | 65.0 |
| 39 | Assure Tech | 64.5 |
| 40 | Asymchem | 64.0 |
| 41 | Hybio | 63.5 |
| 42 | HitGen | 63.0 |
| 43 | Chison | 62.5 |
| 44 | Chempartner | 62.0 |
| 45 | Shenzhen Glory | 61.5 |
| 46 | Guangdong Transtek | 61.0 |
| 47 | Mehow Innovative | 60.5 |
| 48 | Nanjing King-Friend | 60.0 |
| 49 | Qianjiang Yongan | 59.5 |
| 50 | Hangzhou Biotest | 59.0 |
| 51 | Honsun | 58.5 |
| 52 | Edan | 58.0 |
| 53 | Huizhou Jinghao | 57.5 |
| 54 | Jiangxi Synergy | 57.0 |
| 55 | Anhui Hongyu Wuzhou | 56.5 |
| 56 | Hangzhou AllTest | 56.0 |
| 57 | Blue Sail | 55.5 |
Table 2. ESG ranking of 57 Chinese pharmaceutical and biotechnology companies (2024). Scores are based on a composite assessment across environmental, social, and governance indicators. Jiangsu Sinopep-Allsino ranks 5th with a score of 86.5.
Read the full article:
Wang, Z.; Lim, T.; Teng, Y.; Xia, C. A Data-Driven Machine Learning Framework for Multi-Criteria ESG Evaluation. Big Data Cogn. Comput. 2026, 10, 130. https://doi.org/10.3390/bdcc10050130
The complete study, including methods, robustness checks, and Supplementary Materials with company-level data, is available open access: https://www.mdpi.com/2504-2289/10/5/130





